Identification of pharmaceuticals of environmental concern MistraPharma will contribute to identifying the active pharmaceutical ingredients on the Swedish market most likely to cause adverse effects in the aquatic environment. The programme will also generate data on which molecular structure elements that are important for biodegradability of pharmaceutical compounds.Recommendations to improve wastewater treatment technologies
MistraPharma will identify and develop wastewater treatment technologies that will help improve the elimination of high-risk pharmaceuticals from waste water treatment plants. Any recommendations to improve waste water treatment will be based on an integrated analysis taking into account what is environmentally motivated, technically feasible and economically realistic.
Improved risk identification strategies
MistraPharma will develop new tools for detecting environmental effects of human pharmaceuticals based on the compounds´ expected pharmacological mechanisms or using explorative methods covering a broad range of biological interactions. Based on these methods MistraPharma will propose new approaches to ecotoxicological testing of pharmaceuticals.
Stakeholder communication
MistraPharma will ensure that the stakeholders, such as the pharmaceutical industry, national, regional and local authorities, waste water treatment plants and, health care, are actively informed about and given access to the new knowledge and expertise that will enable them to limit the effects of human pharmaceuticals in the aquatic environment.
